PharmacoEconomics

1997 - 2025

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 36, issue 12, 2018

Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues pp. 1395-1405

Patricia Danzon

Multi-Indication Pricing: Nice in Theory but Can it Work in Practice? pp. 1407-1420

Jorge Mestre-Ferrandiz, Néboa Zozaya, Bleric Alcalá and Álvaro Hidalgo-Vega

Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models pp. 1421-1426

Anthony J. Hatswell, Ash Bullement, Andrew Briggs, Mike Paulden and Matthew D. Stevenson

Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 1427-1437

Iñigo Bermejo, Shijie Ren, Emma Simpson, Mark Clowes, David L. Scott, Adam Young and Matt Stevenson

The Future of Precision Medicine: Potential Impacts for Health Technology Assessment pp. 1439-1451

James Love-Koh, Alison Peel, Juan Carlos Rejon-Parrilla, Kate Ennis, Rosemary Lovett, Andrea Manca, Anastasia Chalkidou, Hannah Wood and Matthew Taylor

Understanding and Identifying Key Issues with the Involvement of Clinicians in the Development of Decision-Analytic Model Structures: A Qualitative Study pp. 1453-1462

Samantha Husbands, Susan Jowett, Pelham Barton and Joanna Coast

Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia pp. 1463-1473

Mark Bounthavong, Javed Butler, Chantal M. Dolan, Jeffrey D. Dunn, Kathryn A. Fisher, Nina Oestreicher, Bertram Pitt, Paul J. Hauptman and David L. Veenstra

Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea pp. 1475-1490

Yun-Kyung Kim, Joon Young Song, Hyeongap Jang, Tae Hyun Kim, Heejo Koo, Lijoy Varghese and Euna Han

Volume 36, issue 11, 2018

Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal pp. 1299-1308

Micah Rose, Jonathan Shepherd, Petra Harris, Karen Pickett and Joanne Lord

Model Structuring for Economic Evaluations of New Health Technologies pp. 1309-1319

Hossein Haji Ali Afzali, Laura Bojke and Jonathan Karnon

Cost Effectiveness of Intra-Articular Hyaluronic Acid and Disease-Modifying Drugs in Knee Osteoarthritis pp. 1321-1331

Jean-Hugues Salmon, Anne-Christine Rat, Isabelle Charlot-Lambrecht, Jean-Paul Eschard, Damien Jolly and Bruno Fautrel

Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer pp. 1333-1343

Mahdi Gharaibeh, Ali McBride, David S. Alberts, Brian Erstad, Marion Slack, Nimer Alsaid, J. Lyle Bootman and Ivo Abraham

Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L pp. 1345-1353

Anna Hobbins, Luke Barry, Dan Kelleher, Koonal Shah, Nancy Devlin, Juan Manuel Ramos Goni and Ciaran O’Neill

Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients pp. 1355-1365

Kristina R. Dahlstrom, Shuangshuang Fu, Wenyaw Chan, Zeena Shelal, Lois M. Ramondetta and David R. Lairson

Inpatient Expenditures Attributable to Hospital-Onset Clostridium difficile Infection: A Nationwide Case–Control Study in Japan pp. 1367-1376

Haruhisa Fukuda, Takahisa Yano and Nobuyuki Shimono

Severity-Stratified Discrete Choice Experiment Designs for Health State Evaluations pp. 1377-1389

Sesil Lim, Marcel F. Jonker, Mark Oppe, Bas Donkers and Elly Stolk

Volume 36, issue 10, 2018

Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions? pp. 1135-1141

John W. Stevens

Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 1143-1151

Rachid Rafia, Abdullah Pandor, Sarah Davis, John W. Stevens, Sue Harnan, Mark Clowes, Youssef Sorour and Robert Cutting

Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 1153-1163

Angela Stainthorpe, Janette Greenhalgh, Adrian Bagust, Marty Richardson, Angela Boland, Sophie Beale, Rui Duarte, Eleanor Kotas, Lindsay Banks and Daniel Palmer

Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review pp. 1165-1200

Carlos E. Rodriguez-Martinez, Monica P. Sossa-Briceño and Jose A. Castro-Rodriguez

Costs of Invasive Meningococcal Disease: A Global Systematic Review pp. 1201-1222

Bing Wang, Renee Santoreneos, Hossein Afzali, Lynne Giles and Helen Marshall

Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations pp. 1223-1252

Luis Hernandez, Malinda O’Donnell and Maarten Postma

Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis pp. 1253-1261

Jesse Elliott, Bláthnaid McCoy, Tammy Clifford, George A. Wells and Doug Coyle

The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study pp. 1263-1272

José Leal, Stefania Manetti and James Buchanan

Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer pp. 1273-1284

Mahdi Gharaibeh, Ali McBride, David S. Alberts, Marion Slack, Brian Erstad, Nimer Alsaid, J. Lyle Bootman and Ivo Abraham

Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany pp. 1285-1296

Afschin Gandjour and Dennis A. Ostwald

Comment on: Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial pp. 1297-1297

Baptiste Leurent, Manuel Gomes and James Carpenter

Volume 36, issue 9, 2018

Are PCSK9 Inhibitors Cost Effective? pp. 1031-1041

Max J. Korman, Kjetil Retterstøl, Ivar Sønbø Kristiansen and Torbjørn Wisløff

A Practical Guide to Conducting a Systematic Review and Meta-analysis of Health State Utility Values pp. 1043-1061

Stavros Petrou, Joseph Kwon and Jason Madan

Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 1063-1072

Lesley Uttley, Iñigo Bermejo, Shijie Ren, Marrissa Martyn-St James, Ruth Wong, David L. Scott, Adam Young and Matt Stevenson

Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal pp. 1073-1081

Xavier Armoiry, Martin Connock, Alexander Tsertsvadze, Ewen Cummins, G. J. Melendez-Torres, Pam Royle and Aileen Clarke

Review of Economic Value Drivers of the Treatment of Overactive Bladder pp. 1083-1092

Sonya J. Snedecor

Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References? pp. 1093-1099

T. Joseph Mattingly, Joseph F. Levy, Julia F. Slejko, Nneka C. Onwudiwe and Eleanor M. Perfetto

Smoking Cessation: A Comparison of Two Model Structures pp. 1101-1112

Becky Pennington, Alex Filby, Lesley Owen and Matthew Taylor

Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor–positive and Human Epidermal Growth Factor Receptor 2–negative Metastatic Breast Cancer in Japan pp. 1113-1124

Verin Lertjanyakun, Nathorn Chaiyakunapruk, Susumu Kunisawa and Yuichi Imanaka

Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO) pp. 1125-1134

Hui Shao, Vivian Fonseca, Charles Stoecker, Shuqian Liu and Lizheng Shi

Volume 36, issue 8, 2018

Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation pp. 883-888

Feng Xie

Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial pp. 889-901

Baptiste Leurent, Manuel Gomes, Rita Faria, Stephen Morris, Richard Grieve and James R. Carpenter

Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 903-915

Abdullah Pandor, Matt Stevenson, John Stevens, Marrissa Martyn-St James, Jean Hamilton, Jenny Byrne, Claudius Rudin, Andrew Rawdin and Ruth Wong

Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 917-927

Bram L. T. Ramaekers, Robert F. Wolff, Xavier Pouwels, Marije Oosterhoff, Anoukh Giessen, Gill Worthy, Caro Noake, Nigel Armstrong, Jos Kleijnen and Manuela A. Joore

Cost Effectiveness of Human Papillomavirus Vaccination for Men Who have Sex with Men; Reviewing the Available Evidence pp. 929-939

Didik Setiawan, Abrham Wondimu, KohJun Ong, Albert Jan Hoek and Maarten J. Postma

Does Non-Adherence Increase Treatment Costs in Schizophrenia? pp. 941-955

Mark Pennington and Paul McCrone

Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations pp. 957-971

R. Brett McQueen, Danielle N. Sheehan, Melanie D. Whittington, Job F. M. Boven and Jonathan D. Campbell

Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment pp. 973-986

Juan Marcos González, Justin Doan, David J. Gebben, Marco Boeri and Mayer Fishman

Applying GRADE Criteria to Clinical Inputs to Cost-Effectiveness Modeling Studies pp. 987-994

Alexander Mensch, Tanja Beck, Daniele Civello, Christopher Kunigkeit, Nicole Lachmann, Stephanie Stock, Afschin Gandjour and Dirk Müller

Effects of County Public Hospital Reform on Procurement Costs and Volume of Antibiotics: A Quasi-Natural Experiment in Hubei Province, China pp. 995-1004

Yuqing Tang, Chaojie Liu, Junjie Liu, Xinping Zhang and Keyuan Zuo

Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors pp. 1005-1013

Chan Shen, Arvind Dasari, Dian Gu, Yiyi Chu, Shouhao Zhou, Ying Xu, Daniel Halperin, Shuangshuang Fu, James C. Yao and Ya-Chen Shih

Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK pp. 1015-1027

Paul Emery, Marjolijn Keep, Steve Beard, Chris Graham, LaStella Miles, Steffen Marc Jugl, Praveen Gunda, Anna Halliday and Helena Marzo-Ortega

Comment on: “Mapping the Paediatric Quality of Life Inventory (PedsQL™) Generic Core Scales Onto the Child Health Utility Index-9 Dimension (CHU-9D) Score for Economic Evaluation in Children” pp. 1029-1029

Emma Frew and Tosin Lambe

Volume 36, issue 7, 2018

Should Low- and Middle-Income Countries Adopt Clinical Guidelines Developed in ‘Rich’ Countries? pp. 731-732

Alan Haycox

Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails? pp. 733-743

Fernando Antoñanzas, Roberto Rodríguez-Ibeas and Carmelo A. Juárez-Castelló

Discounting in Economic Evaluations pp. 745-758

Arthur Attema, Werner Brouwer and Karl Claxton

Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 759-768

Matt Stevenson, Abdullah Pandor, Jean Hamilton, John Stevens, Clare Rowntree, Marrissa Martyn-St James, Andrew Rawdin and Ruth Wong

Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 769-778

Shijie Ren, Iñigo Bermejo, Emma Simpson, Ruth Wong, David L. Scott, Adam Young and Matt Stevenson

The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review pp. 779-807

Alex Diamantopoulos, Emily Wright, Katerina Vlahopoulou, Laura Cornic, Nils Schoof and Toby M. Maher

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin pp. 809-822

Guy Neff and Woodie Zachry

The Role of Measurement Uncertainty in Health Technology Assessments (HTAs) of In Vitro Tests pp. 823-835

Alison F. Smith, Mike Messenger, Peter Hall and Claire Hulme

Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England pp. 837-851

Irina A. Tikhonova, Nicola Huxley, Tristan Snowsill, Louise Crathorne, Jo Varley-Campbell, Mark Napier and Martin Hoyle

Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist pp. 853-865

Przemysław Holko, Paweł Kawalec and Andrzej Pilc

Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK pp. 867-878

Vanessa Buchanan, Will Sullivan, Chris Graham, LaStella Miles, Steffen Marc Jugl, Praveen Gunda, Anna Halliday and Bruce Kirkham

Comment on: “A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis” pp. 879-879

Ena Singh

Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin pp. 881-881

Guy Neff and Woodie Zachry

Volume 36, issue 6, 2018

3L, 5L, What the L? A NICE Conundrum pp. 637-640

Nancy Devlin, John Brazier, A. Simon Pickard and Elly Stolk

Once Bitten Twice Shy: Thinking Carefully Before Adopting the EQ-5D-5L pp. 641-643

Jeff Round

A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D pp. 645-661

Ines Buchholz, Mathieu F. Janssen, Thomas Kohlmann and You-Shan Feng

German Value Set for the EQ-5D-5L pp. 663-674

Kristina Ludwig, Johann Graf von der Schulenburg and Wolfgang Greiner

Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries pp. 675-697

Mathieu F. Janssen, Gouke J. Bonsel and Nan Luo

Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets pp. 699-713

Brendan Mulhern, Yan Feng, Koonal Shah, Mathieu F. Janssen, Michael Herdman, Ben Hout and Nancy Devlin

Head-to-Head Comparison of EQ‐5D‐3L and EQ‐5D‐5L Health Values pp. 715-725

Anna Selivanova, Erik Buskens and Paul F. M. Krabbe

Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets pp. 727-727

Brendan Mulhern, Yan Feng, Koonal Shah, Mathieu F. Janssen, Michael Herdman, Ben Hout and Nancy Devlin

Correction to: 3L, 5L, What the L? A NICE Conundrum pp. 729-729

Nancy Devlin, John Brazier, A. Simon Pickard and Elly Stolk

Volume 36, issue 5, 2018

Cost-Effectiveness Thresholds: the Past, the Present and the Future pp. 509-522

Praveen Thokala, Jessica Ochalek, Ashley A. Leech and Thaison Tong

Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities pp. 523-532

Edna Keeney, Dalia Dawoud and Sofia Dias

Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 533-543

Xavier G. L. V. Pouwels, Robert Wolff, Bram L. T. Ramaekers, Anoukh Giessen, Shona Lang, Steve Ryder, Gill Worthy, Steven Duffy, Nigel Armstrong, Jos Kleijnen and Manuela A. Joore

Reslizumab for Treating Asthma with Elevated Blood Eosinophils Inadequately Controlled by Inhaled Corticosteroids: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 545-553

Keith Cooper, Geoff Frampton, Petra Harris, Micah Rose, Maria Chorozoglou and Karen Pickett

The Australian Managed Entry Scheme: Are We Getting it Right? pp. 555-565

Haitham W. Tuffaha and Paul Scuffham

Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review pp. 567-589

Lucia Sara D’Angiolella, Paolo Angelo Cortesi, Alessandra Lafranconi, Mariangela Micale, Sveva Mangano, Giancarlo Cesana and Lorenzo Giovanni Mantovani

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway pp. 591-601

Torbjørn Wisløff, Richard White, Olav Dalgard, Ellen J. Amundsen, Hinta Meijerink, Astrid Louise Løvlie and Hilde Kløvstad

A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet pp. 603-612

Björn Stollenwerk, Sergio Iannazzo, Ron Akehurst, Michael Adena, Andrew Briggs, Bastian Dehmel, Patrick Parfrey and Vasily Belozeroff

New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes pp. 613-624

Alice Varnava, Robert Bracchi, Karen Samuels, Dyfrig A. Hughes and Philip A. Routledge

Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy pp. 625-636

Matteo Ruggeri, M. Basile, Carlo Drago, F. R. Rolli and A. Cicchetti

Volume 36, issue 4, 2018

Is ICER NICEr? pp. 385-386

Deborah Freund and Jennifer Choi

Ustekinumab for Treating Moderately to Severely Active Crohn’s Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 387-398

Robert Hodgson, Matthew Walton, Mousumi Biswas, Teumzghi Mebrahtu and Nerys Woolacott

Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 399-406

Hema Mistry, Chidozie Nduka, Martin Connock, Jill Colquitt, Theodoros Mantopoulos, Emma Loveman, Renata Walewska and James Mason

The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA) pp. 407-417

Salah Ghabri, Erwan Autin, Anne-Isabelle Poullié and Jean Michel Josselin

A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis pp. 419-434

Ewa Stawowczyk and Paweł Kawalec

Cost Effectiveness of Treatments for Chronic Constipation: A Systematic Review pp. 435-449

Dolly Han, Nicolas Iragorri, Fiona Clement, Diane Lorenzetti and Eldon Spackman

Mapping the Paediatric Quality of Life Inventory (PedsQL™) Generic Core Scales onto the Child Health Utility Index–9 Dimension (CHU-9D) Score for Economic Evaluation in Children pp. 451-465

Tosin Lambe, Emma Frew, Natalie J. Ives, Rebecca L. Woolley, Carole Cummins, Elizabeth A. Brettell, Emma N. Barsoum and Nicholas J. A. Webb

The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011–2017 pp. 467-475

Chris Skedgel, Dominika Wranik and Min Hu

Treatment Preferences in Germany Differ Among Apheresis Patients with Severe Hypercholesterolemia pp. 477-493

Axel C. Mühlbacher, Andrew Sadler, Franz-Werner Dippel and Christin Juhnke

Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer pp. 495-504

Josh J. Carlson, Kangho Suh, Panos Orfanos and William Wong

Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy pp. 505-505

Amir Ansaripour, Carin A. Uyl- de Groot and W. Ken Redekop

Correction to: Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Clinical Excellence Single Technology Appraisal pp. 507-507

Irina A. Tikhonova, Tracey Jones-Hughes, James Dunham, Fiona C. Warren, Sophie Robinson, Peter Stephens and Martin Hoyle

Volume 36, issue 3, 2018

Price Transparency for Whom? In Search of Out-of-Pocket Cost Estimates to Facilitate Cost Communication in Cancer Care pp. 259-261

Ya-Chen Shih, Shelley Fuld Nasso and S. Yousuf Zafar

Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions pp. 263-284

Paolo A. Cortesi, Lucia S. D’Angiolella, Alessandra Lafranconi, Mariangela Micale, Giancarlo Cesana and Lorenzo G. Mantovani

Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 285-288

Bram L. T. Ramaekers, Robert Wolff, Anoukh Giessen, Xavier Pouwels, Debra Fayter, Shona Lang, Nigel Armstrong, Gill Worthy, Steven Duffy, Jos Kleijnen and Manuela A. Joore

Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 289-299

Nigel Fleeman, Ahmed Abdulla, Adrian Bagust, Sophie Beale, Marty Richardson, Angela Stainthorpe, Angela Boland, Eleanor Kotas, Joanne McEntee and Daniel Palmer

Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review pp. 301-322

Lazaros Andronis, Ilias Goranitis, Sue Bayliss and Rui Duarte

Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review pp. 323-340

Peter Ghijben, Yuanyuan Gu, Emily Lancsar and Silva Zavarsek

A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis pp. 341-347

Shijie Ren, Jonathan Minton, Sophie Whyte, Nicholas R. Latimer and Matt Stevenson

Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis pp. 349-358

Rebekah Fong Soe Khioe, Chris Skedgel, Andrew Hart, Michael Philip Nelson Lewis and Leo Alexandre

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies pp. 359-368

Amr Makady, Ard Veelen, Páll Jonsson, Owen Moseley, Anne D’Andon, Anthonius Boer, Hans Hillege, Olaf Klungel and Wim Goettsch

Sensitivity of the Medication Possession Ratio to Modelling Decisions in Large Claims Databases pp. 369-380

Margret V. Bjarnadottir, David Czerwinski and Eberechukwu Onukwugha

Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’ pp. 381-382

Amir Ansaripour, Carin A. Uyl- de Groot and W. Ken Redekop

Optimality, Future and Terminal Costs: Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran” pp. 383-384

Noga Gershon and Yakir Berchenko

Volume 36, issue 2, 2018

Towards a New Framework for Addressing Structural Uncertainty in Health Technology Assessment Guidelines pp. 127-130

Salah Ghabri, Irina Cleemput and Jean-Michel Josselin

Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 131-144

Iñigo Bermejo, Matt Stevenson, Katy Cooper, Sue Harnan, Jean Hamilton, Mark Clowes, Christopher Carroll, Tim Harrison and Shironjit Saha

Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal pp. 145-159

Nasuh C. Büyükkaramikli, Saskia Groot, Debra Fayter, Robert Wolff, Nigel Armstrong, Lisa Stirk, Gill Worthy, Fernando Albuquerque de Almeida, Jos Kleijnen and Maiwenn J. Al

The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil pp. 161-173

Livia Lovato Pires de Lemos, Augusto Afonso Guerra Júnior, Marisa Santos, Carlos Magliano, Isabela Diniz, Kathiaja Souza, Ramon Gonçalves Pereira, Juliana Alvares, Brian Godman, Marion Bennie, Ivan Ricardo Zimmermann, Vânia Crisitna Canuto Santos, Clarice Alegre Pretramale and Francisco de Assis Acurcio

Using Latent Class Analysis to Model Preference Heterogeneity in Health: A Systematic Review pp. 175-187

Mo Zhou, Winter Maxwell Thayer and John F. P. Bridges

Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies pp. 189-204

Sergio Iannazzo, Ange-Christelle Iliza and Louise Perrault

Systematic Review of Validity Assessments of Framingham Risk Score Results in Health Economic Modelling of Lipid-Modifying Therapies in Europe pp. 205-213

Jonas Hermansson and Thomas Kahan

Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study pp. 215-223

Yasuhiro Hagiwara, Takeru Shiroiwa, Kojiro Shimozuma, Takuya Kawahara, Yukari Uemura, Takanori Watanabe, Naruto Taira, Takashi Fukuda, Yasuo Ohashi and Hirofumi Mukai

Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30 pp. 225-238

Madeleine T. King, Rosalie Viney, A. Simon Pickard, Donna Rowen, Neil K. Aaronson, John Brazier, David Cella, Daniel S. J. Costa, Peter M. Fayers, Georg Kemmler, Helen McTaggart-Cowen, Rebecca Mercieca-Bebber, Stuart Peacock, Deborah J. Street, Tracey A. Young and Richard Norman

Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System pp. 239-252

Laura Catherine Edney, Hossein Haji Ali Afzali, Terence Cheng and Jonathan Karnon

Current UK Practices on Health Economics Analysis Plans (HEAPs): Are We Using Heaps of Them? pp. 253-257

Melina Dritsaki, Alastair Gray, Stavros Petrou, Susan Dutton, Sarah E. Lamb and Joanna C. Thorn

Volume 36, issue 1, 2018

Value-Based Pricing: Do Not Throw Away the Baby with the Bath Water pp. 1-3

Mattias Neyt

Value-Based Pricing: L’Enfant Terrible? pp. 5-6

Sarah Garner, Andrew Rintoul and Suzanne R. Hill

Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment pp. 7-15

Jaclyn Beca, Don Husereau, Kelvin K. W. Chan, Neil Hawkins and Jeffrey Hoch

Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices: An Updated Review pp. 17-27

Alisha Monnette, Yichen Zhang, Hui Shao and Lizheng Shi

Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 29-38

Hazel Squires, Abdullah Pandor, Praveen Thokala, John W. Stevens, Eva Kaltenthaler, Mark Clowes, Robert Coleman and Lynda Wyld

Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal pp. 39-49

Irina A. Tikhonova, Tracey Jones-Hughes, James Dunham, Fiona C. Warren, Sophie Robinson, Peter Stephens and Martin Hoyle

The Use of Decision–Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal pp. 51-66

Emma McManus, Tracey Sach and Nick Levell

Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis pp. 67-78

Samuel Herzog, Marian Shanahan, Peter Grimison, Anh Tran, Nicole Wong, Nicholas Lintzeris, John Simes, Martin Stockler and Rachael L. Morton

Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework pp. 79-90

Natalie Carvalho, Mark Jit, Sarah Cox, Joanne Yoong and Raymond C. W. Hutubessy

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy pp. 91-103

Amir Ansaripour, Carin A. Uyl- de Groot and W. Ken Redekop

Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research pp. 105-113

Thea Asselt, Bram Ramaekers, Isaac Corro Ramos, Manuela Joore, Maiwenn Al, Ivonne Lesman-Leegte, Maarten Postma, Pepijn Vemer and Talitha Feenstra

Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease pp. 115-126

Usha G. Mallya, Susan H. Boklage, Andrew Koren, Thomas E. Delea and C. Daniel Mullins